“In addressing the evolving needs of our customers and the molecular testing market, we enable them to provide more efficient and more effective care for their patients,” confirms Dr. David Stein, Head of Strategy & Innovation, Siemens Healthineers. “This exciting step forward, alongside our newest team members from FTD, is the latest example of our ongoing commitment to our molecular diagnostics customers and their patients.”

Through the acquisition, Siemens Healthineers will now include FTD’s sites in Luxembourg, Malta, and India, as well as its workforce of about 80 employees. FTD will continue to operate under the brand name Fast Track Diagnostics throughout the world.


This press release is available at: http://www.siemens.com/press/PR2017120115HCEN

1The products/features (mentioned herein) are not commercially available in all countries. Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability. Please contact your local Siemens Healthineers organization for further details.

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to achieve better outcomes at lower costs by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.

In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens.com/healthineers.

Back to HCB News

Business Affairs Homepage